InnoCare Pharma Future Growth
Future criteria checks 2/6
InnoCare Pharma is forecast to grow earnings and revenue by 26.4% and 26.6% per annum respectively. EPS is expected to grow by 29.3% per annum. Return on equity is forecast to be -10.8% in 3 years.
Key information
26.4%
Earnings growth rate
29.3%
EPS growth rate
| Biotechs earnings growth | 34.9% |
| Revenue growth rate | 26.6% |
| Future return on equity | -10.8% |
| Analyst coverage | Good |
| Last updated | 19 Jun 2024 |
Recent future growth updates
Recent updates
Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?
Jun 21
Some Analysts Just Cut Their InnoCare Pharma Limited (HKG:9969) Estimates
Apr 02Is InnoCare Pharma (HKG:9969) Weighed On By Its Debt Load?
Feb 14Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt?
Oct 06Is InnoCare Pharma (HKG:9969) Using Too Much Debt?
May 11Is There An Opportunity With InnoCare Pharma Limited's (HKG:9969) 36% Undervaluation?
Apr 11Is InnoCare Pharma (HKG:9969) A Risky Investment?
Jan 25Despite Lacking Profits InnoCare Pharma (HKG:9969) Seems To Be On Top Of Its Debt
Sep 05InnoCare Pharma (HKG:9969) Is Using Debt Safely
Apr 30InnoCare Pharma Limited's (HKG:9969) Intrinsic Value Is Potentially 100% Above Its Share Price
Nov 13Despite Lacking Profits InnoCare Pharma (HKG:9969) Seems To Be On Top Of Its Debt
Oct 18Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,754 | -311 | -76 | -416 | 5 |
| 12/31/2025 | 1,260 | -592 | -222 | -550 | 6 |
| 12/31/2024 | 887 | -725 | -665 | -485 | 5 |
| 3/31/2024 | 715 | -761 | -832 | -595 | N/A |
| 12/31/2023 | 739 | -631 | -920 | -665 | N/A |
| 9/30/2023 | 721 | -584 | -760 | -542 | N/A |
| 6/30/2023 | 757 | -867 | -818 | -607 | N/A |
| 3/31/2023 | 696 | -781 | -716 | -507 | N/A |
| 12/31/2022 | 625 | -887 | -861 | -491 | N/A |
| 9/30/2022 | 503 | -987 | -888 | -508 | N/A |
| 6/30/2022 | 1,187 | -296 | -229 | 150 | N/A |
| 3/31/2022 | 1,111 | -78 | -226 | 117 | N/A |
| 12/31/2021 | 1,043 | -65 | -4 | 167 | N/A |
| 9/30/2021 | 982 | 60 | 49 | 239 | N/A |
| 6/30/2021 | 102 | -266 | -464 | -258 | N/A |
| 3/31/2021 | 52 | -329 | -444 | -215 | N/A |
| 12/31/2020 | 1 | -391 | -424 | -173 | N/A |
| 9/30/2020 | 1 | -1,853 | -393 | -148 | N/A |
| 6/30/2020 | 1 | -2,155 | -320 | -137 | N/A |
| 3/31/2020 | 1 | -2,148 | -237 | -108 | N/A |
| 12/31/2019 | 1 | -2,141 | -155 | -80 | N/A |
| 9/30/2019 | 2 | -742 | -43 | -30 | N/A |
| 6/30/2019 | 2 | -592 | -22 | -17 | N/A |
| 3/31/2019 | 2 | -571 | -30 | -18 | N/A |
| 12/31/2018 | 2 | -550 | -38 | -18 | N/A |
| 12/31/2017 | 0 | -342 | N/A | -49 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 9969 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 9969 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 9969 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 9969's revenue (26.6% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).
High Growth Revenue: 9969's revenue (26.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 9969 is forecast to be unprofitable in 3 years.